Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation

Prenatal Diagnosis

Volumn 28, Issue 13, 2008, Pages 1209-1213

  Kagan, Karl O ^a,b   Anderson, James M ^a   Anwandter, Gabriel ^a   Neksasova, Katya ^a   Nicolaides, Kypros H ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Fetal and placental pathology; Fetal imaging; Fetal ultrasound; First trimester screening; Maternal serum screening; Nuchal translucency; Triplody

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; EDWARDS SYNDROME; FEMALE; FETUS HEART RATE; GESTATION PERIOD; HORMONE BLOOD LEVEL; HUMAN; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PRENATAL SCREENING; PRIORITY JOURNAL; RISK ASSESSMENT; TRIPLOIDY; TRISOMY 13;

ADOLESCENT; ADULT; ALGORITHMS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 18; DOWN SYNDROME; FEMALE; HEART RATE, FETAL; HUMANS; INFANT, NEWBORN; MIDDLE AGED; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROSPECTIVE STUDIES; TRISOMY; YOUNG ADULT;

EID: 58049206883     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2149     Document Type: Article

References (13)

1. Breathnach FM, Malone FD, Lambert-Messerlian G, et al. 2007. First- and second-trimester screening: detection of aneuploidies other than Down syndrome. Obstet Gynecol 110: 651-657.
2. Jacobs PA, Angell RR, Buchanan IM, Hassold TJ, Matsuyama JS, Manuel B. 1978. The origin of human triploids. Ann Hum Genet 42: 49-57.
3. Jauniaux E, Brown R, Snijders RJM, Noble P, Nicolaides KH. 1997. Early prenatal diagnosis of triploidy. Am J Obstet Gynecol 176: 550-554.
4. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH. 2008a. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotrophin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 31: 493-502.
5. Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH. 2008b. Screening for trisomy 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free β-hCG and pregnancy-associated plasma protein-A. Human Reprod 19: 1968-1975.
6. McFadden DE, Kwong LC, Yam IYL, Langlois S. 1993. Parental origin of triploidy in human fetuses: evidence for genomic imprinting. Hum Genet 92: 465-469.
7. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. 2005. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 25: 221-226.
8. Office for National Statistics. 2000-2002. Birth Statistics. Review of the Registrar General on Births and Patterns of Family Building in England and Wales, Series FM1, No. 29-31 . Stationary Office: London.
9. Salomon LJ, Bernard JP, Nizard J, Ville Y. 2005. First-trimester screening for fetal triploidy at 11 to 14 weeks: a role for fetal biometry. Prenat Diagn 25: 479-483.
10. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. 1998. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 352: 343-346.
11. Snijders RJM, Sebire NJ, Nicolaides KH. 1995. Maternal age and gestational age-specific risk for chromosomal defects. Fetal Diagn Ther 10: 356-367.
12. Spencer K, Liao AW, Skentou H, Cicero S, Nicolaides KH. 2000. Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20: 495-499.
13. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH. 2008. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 31: 376-383.